Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever This table compares Atyr PHARMA and CG Oncology’s net margins, return on ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company ...

aTyr Pharma, Inc. announced the appointment of Eric Benevich to its Board of Directors, effective December 10, 2024. Benevich, currently the Chief Commercial Officer at Neurocrine Biosciences ...

Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact [email protected]. aTyr is a clinical ...

“We are pleased to report yet another positive safety review for efzofitimod, which includes all 268 patients that have been enrolled in our global pivotal Phase 3 EFZO-FIT ™ study,” said ...